Renato G. Martins, MD, MPH
I’ve always known lung diseases impact patients and their families in profound ways, because my own father had cancer. Also, both he and my grandfather were pulmonologists specializing in treating respiratory diseases. In my challenging yet focused work with lung, head and neck cancers (from Rio de Janeiro to Seattle), I’ve dedicated myself to compassionate care and to advancing treatments that reduce the devastating impact of these diseases. When I completed my early training, I knew every two-year survivor of lung cancer by name — because there were so few. Today, because of SCCA’s advanced research and treatments, I’m seeing five-year survival for patients with advanced cancer. Things have changed dramatically.
Caring for you as my patient includes listening deeply. I’m here to attend to your unique needs as well as your family's. At SCCA, you’ll receive the very best possible care, because our highly specialized teams focus on developing new advances in immunotherapy to offer patients new hope. You literally have access to tomorrow’s treatments, today. My goal is to increase the number of cancer patients that we’re able to cure. When a cancer is not curable, we diligently focus all our accumulated knowledge and experience on getting your disease under control so you can return to doing things you enjoy and living a productive life with a chronic health problem that is manageable.
Specialty: Medical Oncology
Though SCCA offers the best cancer treatment available, I feel we can do even better. Through clinical research, we can advance treatments even further to improve our patients’ quality of life and help create more survivors of head and neck cancers. That's why my research is focused on immunotherapy, targeted therapies and designing clinical trials for head and thoracic cancers. I’ve contributed to over 80 publications and authored clinical trials that led to new therapies being used up to 73 months before FDA approval.
Today is a completely different medical landscape than just five years ago. The difference in a huge part is due to SCCA being at the forefront of developing cellular immunotherapies and the new therapies available. Our treatments administer cancer-fighting immune cells in combination with drugs that stimulate the immune system. For some lung cancer patients, a checkpoint inhibitor is now the preferred first-line therapy — before chemotherapy — to prevent cancer from blocking your body’s immune response.
Stories and testimonials
Throughout this unprecedented global crisis, Seattle Cancer Care Alliance (SCCA) has developed and enacted new protocols to ensure safety for our patients, staff, and community. As Washington State successfully flattened the COVID-19 curve, we’ve re-opened services that were deferred amid the outbreak.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.
SCCA's Renato Martins, MD, recently discussed the treatment landscape and approaches to care for non-small cell lung cancer.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.